Loading clinical trials...
Loading clinical trials...
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Conditions
Interventions
Lenalidomide
Rituximab
Locations
97
Belgium
ZNA Stuivenberg
Antwerp, Belgium
A. Z. Sint-Jan
Bruges, Belgium
Institut Jules Bordet
Brussels, Belgium
Université Catholique de Louvain Saint Luc
Brussels, Belgium
Hôpital Erasme
Brussels, Belgium
Grand Hôpital de Charleroi
Charleroi, Belgium
Start Date
August 1, 2014
Primary Completion Date
November 5, 2018
Completion Date
January 1, 2021
Last Updated
April 13, 2021
NCT05006716
NCT06026319
NCT07368270
NCT07255963
NCT05940272
NCT06352242
Lead Sponsor
The Lymphoma Academic Research Organisation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions